The New Reality Of Particulate Risk: What Drug Manufacturers Need To Know

Particulate contamination accounts for 37% of US FDA injectable drug recalls, and the regulatory environment is becoming more demanding: FDA now requires injectables to be "essentially free" of visible particulates under USP <790>, while the EU GMP Annex 1 revision mandates a site-wide contamination control strategy covering particulates, microbes, and pyrogens.

At the same time, the injectable market has grown from $498 to $818 billion, and the proportion of particulate-sensitive products continues to rise. This infographic frames the scale of the challenge and outlines the manufacturing and component strategies, including advanced materials, Quality by Design, and automated 100% vision inspection, that support a low-particulate environment. Explore the data and see where the compliance bar now sits.